The startup develops biopharmaceutical therapies targeting rare and severe diseases through the creation of novel drug candidates utilizing two specific molecular compounds. With a management team experienced in orphan disease treatment, the company aims to provide effective therapeutic options for patients with limited treatment alternatives.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with rare and severe diseases often face a lack of effective therapeutic options, resulting in unmet medical needs and limited improvements in their quality of life. The development of treatments for these conditions is challenging due to the complexity of the diseases and the limited number of patients available for clinical trials.
Solution
AltiBio is a biopharmaceutical company focused on developing novel drug candidates for rare and severe diseases. The company utilizes two specific molecular compounds to create targeted therapies that address the underlying causes of these conditions. AltiBio's pipeline includes multiple projects in development, with the lead product candidate currently undergoing IND enabling activities. The company aims to provide relief and improve the lives of patients with limited treatment alternatives by advancing its drug candidates through clinical development and regulatory approval.
Target Audience
The primary target audience includes patients suffering from rare and severe diseases, as well as their families and caregivers, and healthcare providers specializing in these conditions.
Features
- Development of novel drug candidates using two specific molecular compounds
- Pipeline includes multiple projects in development (ATB226, ATB227, and ATB228)
- Lead product candidate (ATB226) currently undergoing IND enabling activities
- Focus on orphan therapeutics for rare and severe diseases